

Technical sheet

Idylla™ BRAF Mutation Assay

The Idylla™ BRAF Mutation Assay, performed on the Biocartis Idylla™ System, is a molecular assay for the qualitative detection of V600E/E2/D and V600K/R/M mutations in codon 600 of the BRAF gene.

The Idylla™ BRAF Mutation Assay, from sample-to-result, starts with formalin-fixed paraffin-embedded (FFPE) tissue to liberate DNA for subsequent real-time PCR amplification and detection.



Features

BRAF mutation detection	
Codon 600	BRAF V600E (c.1799T>A)
	BRAF V600E2 (c.1799_1800delinsAA)
	BRAF V600D (c.1799_1800delinsAT; c.1799_1800delinsAC)
	BRAF V600K (c.1798_1799delinsAA)
	BRAF V600R (c.1798_1799delinsAG)
	BRAF V600M (c.1798G>A)
	BRAF Wild Type (c.1799T)
RNaseP (acting as Sample Processing Control)	
Specimen requirements	
Sample Type	FFPE tissue sections (5 to 10µm)
Neoplastic cells	≥50%, if less macrodissection is required
Tissue area	50-600mm ² (5µm) 25-300mm ² (10µm)
Total turnaround time	
Time	90 minutes
Result Reporting	
Report	Qualitative genotype call

Disclaimer

Biocartis trademark and logo are trademarks belonging to Biocartis and are used and registered in Europe. Idylla is a registered trademark in the United States (US) and other countries. Idylla trademark and logo are used trademarks belonging to Biocartis. Idylla™ platform is a CE-marked IVD in Europe. Idylla™ BRAF Mutation Assay is available for Research Use Only (RUO), not for use in diagnostic procedures.